Efficacy and Safety Study of Enzalutamide in Combination With Exemestane in Patients With Advanced Breast Cancer
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02007512 |
Recruitment Status :
Active, not recruiting
First Posted : December 10, 2013
Results First Posted : February 6, 2018
Last Update Posted : April 26, 2024
|
Sponsor:
Pfizer
Collaborators:
Astellas Pharma Inc
Medivation, Inc.
Information provided by (Responsible Party):
Pfizer
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Study Type | Interventional |
---|---|
Study Design | Allocation: Randomized; Intervention Model: Parallel Assignment; Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor); Primary Purpose: Treatment |
Condition |
Breast Cancer |
Interventions |
Drug: Enzalutamide Drug: exemestane Drug: Placebo (for enzalutamide) |
Enrollment | 247 |
Participant Flow
Recruitment Details | |
Pre-assignment Details | This was a phase 2, randomized, double blind, placebo-controlled study. The results disclosed in this draft were based on the data collected till 23 Sep 2016. |
Arm/Group Title | Cohort 1: Enzalutamide 160 mg + Exemestane 50 mg | Cohort 1: Placebo + Exemestane 25 mg | Cohort 2: Enzalutamide 160 mg + Exemestane 50 mg | Cohort 2: Placebo + Exemestane 25 mg |
---|---|---|---|---|
Arm/Group Description | Participants with no previous hormonal treatment for advanced breast cancer, received enzalutamide 160 mg along with exemestane 50 mg, orally, once daily until disease progression or permanent treatment discontinuation. Participants were followed-up until 30 days after last dose of study drug, death, or before initiation of a new antitumor treatment, whichever occurred first. | Participants with no previous hormonal treatment for advanced breast cancer received placebo matched to enzalutamide along with exemestane 25 mg, orally, once daily in double blind treatment period until disease progression or permanent treatment discontinuation. Eligible participants with disease progression in double blind period, on their discretion, received enzalutamide 160 mg along with exemestane 50 mg, orally, once daily up to disease progression in open label treatment period. Participants were followed-up until 30 days after last dose of study drug, death, or before initiation of a new antitumor treatment, whichever occurred first. | Participants with previous disease progression following hormonal treatment for advanced breast cancer, received enzalutamide 160 mg along with exemestane 50 mg, orally, once daily in double blind treatment period until disease progression or permanent treatment discontinuation. Participants were followed-up until 30 days after last dose of study drug, death, or before initiation of a new antitumor treatment, whichever occurred first. | Participants with previous disease progression following hormonal treatment for advanced breast cancer, received placebo matched to enzalutamide along with exemestane 25 mg, orally, once daily in double blind treatment period until disease progression or permanent treatment discontinuation. Eligible participants with disease progression in double blind period, on their discretion, received enzalutamide 160 mg along with exemestane 50 mg, orally, once daily up to disease progression in open label treatment period. Participants were followed-up until 30 days after last dose of study drug, death, or before initiation of a new antitumor treatment, whichever occurred first. |
Period Title: Double Blind Treatment Period | ||||
Started | 63 | 64 | 60 | 60 |
Treated | 62 | 63 | 60 | 60 |
Completed | 0 | 0 | 0 | 0 |
Not Completed | 63 | 64 | 60 | 60 |
Reason Not Completed | ||||
Adverse Event | 4 | 2 | 6 | 2 |
Death | 1 | 0 | 0 | 0 |
Disease progression | 44 | 49 | 45 | 51 |
Withdrawal by Subject | 4 | 2 | 3 | 3 |
Protocol Violation | 0 | 0 | 0 | 1 |
Other | 0 | 0 | 1 | 2 |
Ongoing as of data cutoff (23 Sep 2016) | 10 | 11 | 5 | 1 |
Period Title: Open Label Treatment Period | ||||
Started | 0 | 21 [1] | 0 | 12 [2] |
Completed | 0 | 0 | 0 | 0 |
Not Completed | 0 | 21 | 0 | 12 |
Reason Not Completed | ||||
Adverse Event | 0 | 1 | 0 | 0 |
Other | 0 | 0 | 0 | 1 |
Disease progression | 0 | 17 | 0 | 11 |
Ongoing as of data cutoff (23 Sep 2016) | 0 | 3 | 0 | 0 |
[1]
Of the participants with disease progression in double blind period, 21 entered open label period.
[2]
Of the participants with disease progression in double blind period, 12 entered open label period.
|
Baseline Characteristics
Arm/Group Title | Cohort 1: Enzalutamide 160 mg + Exemestane 50 mg | Cohort 1: Placebo + Exemestane 25 mg | Cohort 2: Enzalutamide 160 mg + Exemestane 50 mg | Cohort 2: Placebo + Exemestane 25 mg | Total | |
---|---|---|---|---|---|---|
Arm/Group Description | Participants with no previous hormonal treatment for advanced breast cancer, received enzalutamide 160 mg along with exemestane 50 mg, orally, once daily until disease progression or permanent treatment discontinuation. Participants were followed-up until 30 days after last dose of study drug, death, or before initiation of a new antitumor treatment, whichever occurred first. | Participants with no previous hormonal treatment for advanced breast cancer received placebo matched to enzalutamide along with exemestane 25 mg, orally, once daily in double blind treatment period until disease progression or permanent treatment discontinuation. Eligible participants with disease progression in double blind period, on their discretion, received enzalutamide 160 mg along with exemestane 50 mg, orally, once daily up to disease progression in open label treatment period. Participants were followed-up until 30 days after last dose of study drug, death, or before initiation of a new antitumor treatment, whichever occurred first. | Participants with previous disease progression following hormonal treatment for advanced breast cancer, received enzalutamide 160 mg along with exemestane 50 mg, orally, once daily in double blind treatment period until disease progression or permanent treatment discontinuation. Participants were followed-up until 30 days after last dose of study drug, death, or before initiation of a new antitumor treatment, whichever occurred first. | Participants with previous disease progression following hormonal treatment for advanced breast cancer, received placebo matched to enzalutamide along with exemestane 25 mg, orally, once daily in double blind treatment period until disease progression or permanent treatment discontinuation. Eligible participants with disease progression in double blind period, on their discretion, received enzalutamide 160 mg along with exemestane 50 mg, orally, once daily up to disease progression in open label treatment period. Participants were followed-up until 30 days after last dose of study drug, death, or before initiation of a new antitumor treatment, whichever occurred first. | Total of all reporting groups | |
Overall Number of Baseline Participants | 63 | 64 | 60 | 60 | 247 | |
Baseline Analysis Population Description |
Intent-to-treat (ITT) population included all the participants randomly assigned to double-blind study treatment.
|
|||||
Age, Categorical
Measure Type: Count of Participants Unit of measure: Participants |
||||||
Number Analyzed | 63 participants | 64 participants | 60 participants | 60 participants | 247 participants | |
<=18 years |
0 0.0%
|
0 0.0%
|
0 0.0%
|
0 0.0%
|
0 0.0%
|
|
Between 18 and 65 years |
42 66.7%
|
32 50.0%
|
37 61.7%
|
40 66.7%
|
151 61.1%
|
|
>=65 years |
21 33.3%
|
32 50.0%
|
23 38.3%
|
20 33.3%
|
96 38.9%
|
|
Sex: Female, Male
Measure Type: Count of Participants Unit of measure: Participants |
||||||
Number Analyzed | 63 participants | 64 participants | 60 participants | 60 participants | 247 participants | |
Female |
63 100.0%
|
64 100.0%
|
60 100.0%
|
60 100.0%
|
247 100.0%
|
|
Male |
0 0.0%
|
0 0.0%
|
0 0.0%
|
0 0.0%
|
0 0.0%
|
Outcome Measures
Adverse Events
Limitations and Caveats
[Not Specified]
More Information
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts
the PI's rights to discuss or publish trial results after the trial is completed.
Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.
Results Point of Contact
Name/Title: | Pfizer ClinicalTrials.gov Call Center |
Organization: | Pfizer, Inc. |
Phone: | 1-800-718-1021 |
EMail: | ClinicalTrials.gov_Inquiries@pfizer.com |
Responsible Party: | Pfizer |
ClinicalTrials.gov Identifier: | NCT02007512 |
Other Study ID Numbers: |
MDV3100-12 2013-002717-35 ( EudraCT Number ) C3431008 ( Other Identifier: Alias Study Number ) |
First Submitted: | December 3, 2013 |
First Posted: | December 10, 2013 |
Results First Submitted: | September 21, 2017 |
Results First Posted: | February 6, 2018 |
Last Update Posted: | April 26, 2024 |